Skip to main content

Table 2 Recurrence risk according to pathological response, Neo-Bioscore and Clustered Neo-Bioscore

From: Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response

Neo-Bioscore All patients pCRc non-pCR
n = 310 DFS-3y (CI95%)a n = 43 DFS-3y (CI95%) n = 267 DFS-3y (CI95%)
0 1 (0.3%) 1.00 0 1.00 1 (0.4%) 1.00
1 18 (5.8%) 1.00 5 (11.6%) 1.00 13 (4.9%) 1.00
2 47 (15.2%) 0.88 (0.81–0.95) 12 (27.9%) 0.89 (0.79–0.99) 35 (13.1%) 0.86 (0.75–0.97)
3 84 (27.1%) 0.83 (0.78–0.88) 11 (25.6%) 0.91 (0.82–1.00) 73 (27.3%) 0.82 (0.76–0.88)
4 83 (26.8%) 0.78 (0.73–0.83) 14 (32.6%) 0.93 (0.87–1.00) 69 (25.8%) 0.74 (0.68–0.80)
5 49 (15.8%) 0.66 (0.57–0.75) 1 (2.3%) 1.00 48 (18.0%) 0.62 (0.51–0.73)
6 23 (7.4%) 0.13 (0.05–0.21) 0 23 (8.6%) 0.13 (0.05–0.21)
7 5 (1.6%) 0 (mTFR = 475 d)b 0 5 (1.9%) 0 (mTFR = 475 d)
Total 0.73 (0.70–0.76) Total 0.92 (0.88–0.96) Total 0.69 (0.65–0.73)
Clustered Neo-Bioscore All patients pCR non-pCR
n = 310 DFS-3y (CI95%) n = 43 DFS-3y (CI95%) n = 267 DFS-3y (CI95%)
0–3 150 0.87 (0.83–0.91) 28 (65.1%) 0.93 (0.87–0.99) 122 (45.7%) 0.86 (0.82–0.90)
4–5 132 0.73 (0.68–0.78) 15 (34.9%) 0.92 (0.86–0.98) 117 (43.8%) 0.70 (0.65–0.75)
6 23 (7.4%) 0.13 (0.05–0.21) 0 23 (8.6%) 0.13 (0.05–0.21)
7 5 (1.6%) 0 (mTFR = 475 d) 0 5 (1.9%) 0 (mTFR = 475 d)
  1. aDFS-3y 3-year disease-free survival rate
  2. bmTFR median time to the first recurrence
  3. cpCR pathological complete response